MCC
SUPN icon

Malaga Cove Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Malaga Cove Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,890
Closed -$316K – 160
2021
Q1 		$316K Sell
11,890
-530
-4% -$14.8K 0.13% 147
2020
Q4 		$310K Sell
12,420
-933
-7% -$20.1K 0.15% 141
2020
Q3 		$278K Hold
13,353
– – 0.16% 136
2020
Q2 		$317K Sell
13,353
-423
-3% -$9.35K 0.19% 130
2020
Q1 		$240K Sell
13,776
-598
-4% -$12.6K 0.2% 130
2019
Q4 		$341K Sell
14,374
-190
-1% -$4.61K 0.21% 126
2019
Q3 		$400K Buy
14,564
+4,384
+43% +$130K 0.27% 118
2019
Q2 		$337K Sell
10,180
-324
-3% -$11.1K 0.22% 126
2019
Q1 		$368K Hold
10,504
– – 0.23% 131
2018
Q4 		$343K Sell
10,504
-480
-4% -$20.6K 0.24% 118
2018
Q3 		$549K Buy
+10,984
New +$542K 0.3% 103

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Malaga Cove Capital's SUPN Position: Q2 2021 in Review

Malaga Cove Capital sold out of Supernus Pharmaceuticals (SUPN) in Q2 2021, closing a stake of 11,890 shares — an estimated $316K sold.

Malaga Cove Capital first reported a position in SUPN in Q3 2018 and held it in 11 quarters. The position peaked at $549K in Q3 2018. 226 funds tracked by Wall St. Rank hold SUPN as of Q2 2021.

  • Malaga Cove Capital reported no remaining Supernus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Malaga Cove Capital sold 11,890 Supernus Pharmaceuticals shares in Q2 2021, an estimated $316K.
  • Malaga Cove Capital first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 11 quarters.
  • Malaga Cove Capital's Supernus Pharmaceuticals position peaked at $549K in Q3 2018.
  • 226 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2021.

Based on Malaga Cove Capital's 13F filing for Q2 2021, filed 27 Jul 2021.